Methods for treating thrombocytopenia
The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.
1. A method for treating chemotherapy-induced thrombocytopenia, comprising administering to a human in need thereof an effective amount of a compound of Formula 2:
2. The method of claim 1 , wherein the compound of Formula 2 is administered in a pharmaceutical composition, which is substantially free of other monoacetyl diacyl glycerol compounds.
3. The method of claim 1 , wherein the compound of Formula 2 is administered in a pharmaceutical composition, which is substantially free of triglyceride compounds.
4. The method of claim 1 , wherein human is suffering from myelosuppressive chemotherapy-induced thrombocytopenia.
5. The method of claim 4 the myelosuppressive chemotherapy-induced thrombocytopenia is caused by a drug selected from among Ziv-aflibercept, Brentuximab vedotin, Pralatrexate, Ganciclovir, Valganciclovir, Romidepsin, Ruxolitinib, Decitabine, Imatinib, Topotecan, Lenalidomide, Irinotecan, Interferons, Phenylhydrazine, Tamoxifen, Lipopolysaccharide, Anthracycline antibiotics, daunorubicin, doxorubicin, Gemcitabine, Cytoxan, Paclitaxel, Alkylating antineoplastic agent, DNA intercalating agent, Alkylating agent, bendamustin, mustard, Topoisomerase inhibitor, Bortezomib, Temsirolimus, Vorinostat, Ifosfamide, and Ixabepilone.
6. The method of claim 4 , wherein the human receives a chemotherapeutic agent selected from one or more of cyclophosphamide, doxorubicin, etoposide, ifosfamide, mesna, cisplatin, gemcitabine, tamoxifen and lenalidomide.
7. The method of claim 4 , wherein the human receives lenalidomide.
8. The method of claim 1 , wherein the human has multiple myeloma, chronic myelogenous leukemia (CML), acute myeloid leukemia, or myelodysplastic syndrome.
9. The method of claim 1 , further comprising administering a G-CSF to the patient.
10. The method of claim 9 , wherein the patient suffers from thrombocytopenia due to treatment with one or more chemotherapeutic agents selected from cyclophosphamide, doxorubicin, etoposide, ifosfamide, mesna, cisplatin, gemcitabine, and tamoxifen.
11. The method of claim 9 , wherein the G-CSF is selected from filgrastim, pegfilgrastim, and lenograstim.
12. The method of claim 1 , wherein administering the compound suppresses upregulated or activated Complement 3 (C3).
13. The method of claim 1 , wherein the compound is administered in the form of a pharmaceutical composition for oral administration.
14. The method of claim 1 , wherein the compound is administered in the form of a pharmaceutical composition which is a soft gelatin capsule containing the compound in combination or association with a pharmaceutically acceptable diluent or carrier.
15. The method of claim 1 , wherein the platelet count of the human does not decrease more than 70 percent.
16. The method of claim 1 wherein a platelet number of the human does not decrease to less than 50,000/μl.
17. The method of claim 1 wherein a platelet number of the human does not decrease to less than 25,000/μl.
18. The method of claim 1 wherein the human is identified as suffering from thrombocytopenia and the compound is administered to the identified human.